skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing

Review

(2462) Views  (627) Full article downloads

Authors: Michel Farnier

Published Date August 2008 Volume 2008:4(5) Pages 991 - 1000
DOI: http://dx.doi.org/10.2147/VHRM.S3390

Michel Farnier

Point Médical, Dijon, France

Abstract: Mixed dyslipidemia is a common lipid disorder characterized by the presence of an atherogenic lipoprotein phenotype due to abnormalities in various atherogenic and antiatherogenic lipoproteins. Despite the link between the decrease of LDL-cholesterol by statin treatment and the prevention of cardiovascular disease, a high residual risk is observed in statin trials. This residual risk is partly explained by lipoprotein abnormalities other than LDL. Fenofibrate exerts a favorable effect on the atherogenic lipid profile of mixed dyslipidemia and can effectively reduce cardiovascular disease in patients with mixed dyslipidemia. Fenofibrate may offer important treatment alternatives as a second-line therapy in several circumstances: in combination with a statin for patients with mixed dyslipidemias not at goals on statin monotherapy; in monotherapy for patients intolerant or with contraindication to statin therapy; and in combination with other drugs (ezetimibe, colesevelam) for patients with mixed dyslipidemias, known intolerance, or contraindication to statin and not at goals on fenofibrate monotherapy. However, the role of fenofibrate-statin therapy and of other therapies involving fenofibrate in cardiovascular risk reduction strategies remains to be established.

Keywords: fenofibrate, mixed dyslipidemia, triglycerides, LDL-cholesterol, HDL-cholesterol








Readers of this article also read:

Update on the use of fibrates: focus on bezafibrate
Habitual coffee consumption and blood pressure: An epidemiological perspective
The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction
Arterial pulmonary hypertension in noncardiac intensive care unit
Antihypertensive effects of astaxanthin
ST segment depression in hypertensive patients: A comparison of exercise test versus Holter ECG
Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study
Cuff inflation during ambulatory blood pressure monitoring and heart rate
Kampo medicines improved blood test and QOL in two vasculitis cases of Churg–Strauss syndrome and Henoch–Shönlein purpura after inadequate treatment with conventional therapies
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University